PharmaCyte Biotech (PMCB) Enterprise Value (2016 - 2026)
PharmaCyte Biotech (PMCB) has disclosed Enterprise Value for 14 consecutive years, with -$15.6 million as the latest value for Q4 2025.
- On a quarterly basis, Enterprise Value rose 25.11% to -$15.6 million in Q4 2025 year-over-year; TTM through Oct 2025 was -$15.6 million, a 25.11% increase, with the full-year FY2025 number at -$15.5 million, up 69.03% from a year prior.
- Enterprise Value was -$15.6 million for Q4 2025 at PharmaCyte Biotech, down from -$13.4 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$959270.0 in Q3 2021 to a low of -$86.9 million in Q4 2021.
- A 5-year average of -$47.0 million and a median of -$55.7 million in 2024 define the central range for Enterprise Value.
- Peak YoY movement for Enterprise Value: plummeted 8471.89% in 2022, then skyrocketed 72.63% in 2025.
- PharmaCyte Biotech's Enterprise Value stood at -$86.9 million in 2021, then grew by 11.47% to -$77.0 million in 2022, then grew by 4.6% to -$73.4 million in 2023, then surged by 71.62% to -$20.8 million in 2024, then grew by 25.11% to -$15.6 million in 2025.
- Per Business Quant, the three most recent readings for PMCB's Enterprise Value are -$15.6 million (Q4 2025), -$13.4 million (Q3 2025), and -$15.5 million (Q2 2025).